Ignite Creation Date:
2024-05-05 @ 10:32 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01121419
Status:
COMPLETED
Last Update Posted:
2010-05-21
First Post:
2010-05-03
Brief Title:
The Role of IMP3 Expression in Patients With Neuroblastoma
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
The Role of IMP3 Expression in Patients With Neuroblastoma
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neuroblastoma NB a common cancer of early childhood originating from primitive sympathetic neural precursors is characterized by the remarkable heterogeneity of clinical behaviors from spontaneous regression to rapid progression and death The current therapeutic options are developed according to the Childrens Oncology Group COG risk stratification criteria based on clinical and biological factors including tumor stage MYCN status age at diagnosis histology and ploidy status 1-2 The treatment strategies ranging from observation alone to intensive multimodality therapy depends on the risk stratification of three subgroups of low intermediate and high risk of death Despite a number of molecular and biologic factors has been identified to predict the prognosis MYCN amplification which occurring in roughly 20 of primary NB is one of the most powerful prognostic factors3 The co-opting neurotrophin pathways including the neurotrophin receptors TrkA TrkB and TrkC and their ligands NGF BDNF and neurotrophin-3 respectively which regulate the differentiation apoptosis and growth of neural cells are also important molecules related to the prognosis of NB4 However a proportion of patients with MYCN nonamplified NB still presents clinically aggressive progression similar to those of MYCN amplified tumors suggesting that other unfavorable molecules exist for the inferior survival5-6 The IGF-II RNA-binding protein 3 IMP3 also known as L532S or K homology domain-containing protein overexpressed in cancer KOC is a member of RNA-binding protein family which includes IMP1 IMP2 and IMP3 The IMPs are primarily expressed during early embryogenesis and have been implicated in various post-transcriptional functions including mRNA localization cell growth and cell migration during early embryogenesis7-8 The IMP3 orthologue Vg1-RBP in Xenopus has also been described to promote migration of neural crest cells9 Recently the IMP3 is considered an oncofetal protein by increasing proliferation and invasion in various cancers including pancreas kidney and lung cancers10-14 The expression of IMP3 is however low or undetectable in adjacent benign tissues13 These lines of evidence indicate that IMP3 is capable of a potential biomarker to predict cancer progression and metastasis and may serve as a target molecule for cancer therapy14
oligonucleotide microarray is a powerful tool to do a genome-wide screening of candidate genes related to cancer prognosis15 In this study 22 primary NB tumors were subjected to oligonucleotide microarray analysis Among the differentially expressed genes according to the patients prognosis IMP3 showed an especially high expression level in NB tumors carrying unfavorable prognosis Further evaluation of IMP3 expression in a large sample size demonstrated that IMP3 expression could predict an unfavorable prognosis of NB patients independent of other biomarkers Targeting of IMP3 expression in a NB cell line did suppress cell invasion ability suggesting that IMP3 could not only be a prognostic factor but also be a potential therapeutic target of NB
oligonucleotide microarray is a powerful tool to do a genome-wide screening of candidate genes related to cancer prognosis15 In this study 22 primary NB tumors were subjected to oligonucleotide microarray analysis Among the differentially expressed genes according to the patients prognosis IMP3 showed an especially high expression level in NB tumors carrying unfavorable prognosis Further evaluation of IMP3 expression in a large sample size demonstrated that IMP3 expression could predict an unfavorable prognosis of NB patients independent of other biomarkers Targeting of IMP3 expression in a NB cell line did suppress cell invasion ability suggesting that IMP3 could not only be a prognostic factor but also be a potential therapeutic target of NB
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None